Royalty Ranges in Biotech Deals
Often the most contentious-and, therefore, closely guarded-aspects of biotech/pharma alliances is the royalties a biotech licenser will receive upon commercialization of the technology or product it has licensed to a partner. We've charted the outside ranges of royalties in biotech deals since 1991 by clinical phase to get a handle on where they tend to fall.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.